A weight-loss percentage on a website can come from a manufacturer trial, an observational study, a customer survey, or a selected testimonial. Those sources answer different questions and should not be treated as interchangeable.

Before accepting a results claim, identify the medicine, study population, duration, accompanying care, and how outcomes were measured. The result does not automatically apply to you.

Approved-product trials

A controlled trial can assess a specific product and regimen under defined conditions. Its average result includes variation among participants. It does not independently test a pharmacy’s compounded preparation.

Read the actual product information and discuss its relevance with the clinician. Do not use a percentage from a different product or population as a personal forecast.

Provider data and testimonials

Observational program data can describe people receiving a service, but may involve selection effects and different treatments. Self-reported customer results have additional measurement limitations.

A compensated testimonial can be an individual’s experience without representing a typical outcome. A prominent transformation picture is not a clinical comparison between providers.

Ask what success means for your plan

The clinician should define treatment goals and monitoring relevant to your health. Price, appearance of a website, and listing order do not establish which program has superior outcomes.

Our RemedyMeds review and Ivím profile explicitly describe different forms of advertised evidence. Use those distinctions in the provider comparison.

Continue your comparison

Compare the GLP-1 programs, read the CoreAge Rx review, and use the program table to prepare questions about the complete offer.

Sources & offer details

Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.

  1. Wegovy: Official product and safety information ↗
  2. Zepbound: Official product and safety information ↗
  3. FDA: Concerns with unapproved GLP-1 drugs ↗